cT2a N0NxM0 Renal Tumor

Clinical trial pipeline · Data from ClinicalTrials.gov

See which cT2a N0NxM0 Renal Tumor trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

All recent trials (1 shown)

CompletedPhase 2

NCT02597322

Study of Axitinib for Downstaging Large Renal Tumors Not Primarily Suitable for Partial Nephrectomy (AXIPAN)

Axitinib (AXITINIB) is an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors 1, 2, and 3 which has achieved objective respons…

France21 participantsStarted 2012-02

Treatment: AXITINIB